Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK2 | P19525 | 4/20 | 0.49 |
| ▸ | AKT1 | P31749 | 7/20 | 0.48 |
| ▸ | NEK1 | Q96PY6 | 2/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.43 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ECE1 | P42892 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4906716 | 0.88 | NEK1 (0.47) | EIF2AK2AKT1NEK1CCNT1CCNA2 | |
| SCHEMBL4895715 | 0.88 | NEK1 (0.47) | EIF2AK2AKT1NEK1CCNT1CCNA2 | |
| SCHEMBL4909073 | 0.85 | ECE1 (0.46) | EIF2AK2AKT1NEK1CCNT1CCNA2 | |
| SCHEMBL4900043 | 0.78 | EIF2AK2 (0.75) | EIF2AK2CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL12845603 | 0.76 | AKT1 (0.52) | AKT1NEK1CDK2CDK9MKNK2 | |
| SCHEMBL3109179 | 0.73 | ROCK2 (0.64) | AKT1CDK2MAPK1ECE1 | |
| SCHEMBL3104497 | 0.73 | ROCK2 (0.64) | AKT1CDK2MAPK1ECE1 | |
| SCHEMBL14159172 | 0.71 | MAPT (0.56) | HSD17B10ECE1 | |
| SCHEMBL13594308 | 0.70 | HTR2A (0.56) | ECE1 | |
| SCHEMBL16203421 | 0.70 | HTR2A (0.56) | ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287452-A1 | HETEROARYL/ARYL PYRIMIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2008-11-20 | — | — | US | claimed |
| US-20080287452-A1 | HETEROARYL/ARYL PYRIMIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287452-A1 | HETEROARYL/ARYL PYRIMIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WNT3A, CTNNB1, WNT1 | EIF2AK2 276/4885AKT1 194/4885NEK1 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.